| Company Name: |
Alfa Chemistry |
| Tel: |
1-516-6625404 |
| Email: |
support@alfa-chemistry.com |
adenosine N1-oxide manufacturers
|
| | adenosine N1-oxide Basic information |
| Product Name: | adenosine N1-oxide | | Synonyms: | 6-AMINO-9-[(2R,3R,4S,5R)-3,4-DIHYDROXY-5-(HYDROXYMETHYL)OXOLAN-2-YL]PURIN-7-IUM-7-OLATE;adenosine N1-oxide;adenosine N(sup 1)-oxide;1-Oxylatoadenosine-1-ium;Adenosine 1-oxide;1-Oxoadenosine;Adenosine N1-Oxide, ANO;ANO | | CAS: | 146-92-9 | | MF: | C10H13N5O5 | | MW: | 283.24 | | EINECS: | 205-683-0 | | Product Categories: | | | Mol File: | 146-92-9.mol |  |
| | adenosine N1-oxide Chemical Properties |
| Melting point | 155 °C | | Boiling point | 777.4±70.0 °C(Predicted) | | density | 2.15±0.1 g/cm3(Predicted) | | pka | 13.03±0.70(Predicted) |
| Hazard Codes | T | | Risk Statements | 25 | | Safety Statements | 45 | | WGK Germany | 3 |
| | adenosine N1-oxide Usage And Synthesis |
| Uses | Adenosine N1-oxide is an oral active anti-inflammatory agent, and can be isolated from royal jelly. Adenosine N1-oxide promotes osteogenic and adipocyte differentiation[1][2]. | | in vivo | Adenosine N1-oxide (oral administration, 135 mg/kg for three times) reduces the lethality caused by LPS (HY-D1056)-induced endotoxin shock in BALB/c mice[1]. | Animal Model: | LPS-induced endotoxin shock in BALB/c mice[1] | | Dosage: | 135 mg/kg for three times | | Administration: | Oral administration | | Result: | Reduced the lethality caused by LPS (HY-D1056)-induced endotoxin shock in BALB/c mice. |
| | References | [1] Kohno K, et al. Anti-inflammatory effects of adenosine N1-oxide. J Inflamm (Lond). 2015;12(1):2. Published 2015 Jan 20. DOI:10.1186/s12950-014-0045-0
[2] Ohashi E, et al. Adenosine N1-Oxide Exerts Anti-inflammatory Effects through the PI3K/Akt/GSK-3β Signaling Pathway and Promotes Osteogenic and Adipocyte Differentiation. Biol Pharm Bull. 2019;42(6):968-976. DOI:10.1248/bpb.b18-00988 |
| | adenosine N1-oxide Preparation Products And Raw materials |
|